董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lynn A. Tetrault | 女 | Chairman of the Board | 63 | 36.52万美元 | 7.37 | 2026-04-14 |
| Jack Kenny | 男 | Director | 58 | 未披露 | 未持股 | 2026-04-14 |
| Anthony P. Zook | -- | Director and Chief Executive Officer | -- | 32.04万美元 | 未持股 | 2026-04-14 |
| Felicia Williams | -- | Independent Director | -- | 30.50万美元 | 0.72 | 2026-04-14 |
| Stephen M. Kanovsky | -- | Independent Director | -- | 30.29万美元 | 5.23 | 2026-04-14 |
| Michael A. Kelly | -- | Independent Director | -- | 31.97万美元 | 4.40 | 2026-04-14 |
| David B. Perez | -- | Independent Director | -- | 31.93万美元 | 3.39 | 2026-04-14 |
| Neil Gunn | -- | Independent Director | -- | 31.25万美元 | 2.81 | 2026-04-14 |
| Marjorie C. Green | -- | Independent Director | -- | 25.68万美元 | 未持股 | 2026-04-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anthony P. Zook | -- | Director and Chief Executive Officer | -- | 32.04万美元 | 未持股 | 2026-04-14 |
| Cynthia J. Dieter | -- | Chief Accounting Officer and Controller | -- | 未披露 | 未持股 | 2026-04-14 |
| Warren C. Stone | -- | President and Chief Operating Officer | -- | 506.88万美元 | 24.03 | 2026-04-14 |
| Gregory D. Aunan | -- | Chief Accounting Officer and Senior Vice President | -- | 未披露 | 未持股 | 2026-04-14 |
| Beth Eastland | -- | Senior Vice President, Enterprise Sales | -- | 未披露 | 未持股 | 2026-04-14 |
| Alicia C. Olivo | 女 | Executive Vice President, Business Development, General Counsel and Corporate Secretary | -- | 305.00万美元 | 11.75 | 2026-04-14 |
| Abhishek Jain | 男 | Chief Financial Officer | -- | 未披露 | 未持股 | 2026-04-14 |
董事简历
中英对照 | 中文 | 英文- Lynn A. Tetrault
-
Lynn A. Tetrault， 2015年6月起担任董事。她目前是顾问。1993-2014年，在AstraZeneca, PLC工作；最近担任人力资源和企业事务执行副总裁。她负责该公司所有的人力资源战略，人才管理，高管薪酬和相关的活动，内部和外部沟通，政府事务，企业信誉和企业的社会责任。她是Princeton大学的本科生；以及是Virginia 大学法学院的法学博士学位。目前是Womens’ Way的董事。
Lynn A. Tetrault has served as a director since June 2015. Mrs. Tetrault is currently a consultant. She worked from 1993 to 2014 with AstraZeneca, PLC most recently as Executive Vice President Human Resources and Corporate Affairs. Mrs. Tetrault was responsible for all human resources strategy, talent management, executive compensation and related activities, internal and external communications, government affairs, corporate reputation and corporate social responsibility for the Company. Mrs. Tetrault has an undergraduate degree from Princeton University and a J.D. from the University of Virginia Law School. - Lynn A. Tetrault， 2015年6月起担任董事。她目前是顾问。1993-2014年，在AstraZeneca, PLC工作；最近担任人力资源和企业事务执行副总裁。她负责该公司所有的人力资源战略，人才管理，高管薪酬和相关的活动，内部和外部沟通，政府事务，企业信誉和企业的社会责任。她是Princeton大学的本科生；以及是Virginia 大学法学院的法学博士学位。目前是Womens’ Way的董事。
- Lynn A. Tetrault has served as a director since June 2015. Mrs. Tetrault is currently a consultant. She worked from 1993 to 2014 with AstraZeneca, PLC most recently as Executive Vice President Human Resources and Corporate Affairs. Mrs. Tetrault was responsible for all human resources strategy, talent management, executive compensation and related activities, internal and external communications, government affairs, corporate reputation and corporate social responsibility for the Company. Mrs. Tetrault has an undergraduate degree from Princeton University and a J.D. from the University of Virginia Law School.
- Jack Kenny
-
Jack Kenny担任Meridian的首席执行官，于2017年10月9日加入该公司。在加入Meridian之前，Kenny先生曾于2014年10月至2017年5月在西门子梦百合担任北美高级副总裁兼总经理。2012年6月至2014年10月，Kenny先生担任诊断系统公司Becton Dickinson的Vice President兼美国地区总经理。2012年6月之前，Kenny先生在丹纳赫公司和Quest Diagnostics担任执行职务。
Jack Kenny,has served as a Director of the Company since August 2023. Mr. Kenny is also an independent member of the board of directors for Quantum Si (NASDAQ: QSI), a protein sequencing company, where he has served since May 2023. Mr. Kenny joined Meridian Biosciences ("Meridian"), a life science and diagnostic company, in October 2017, where he served as the Chief Executive Officer and as a member of the board of directors. Mr. Kenny led Meridian's turnaround resulting in the company's sale in January 2023 (to SJL Partners and SD Biosensor). Before his tenure at Meridian, from 2014 to May 2017, Mr. Kenny served as Senior Vice President and General Manager, North America, of Siemens Healthcare, a healthcare company providing healthcare solutions and services. From 2012 to 2014, Mr. Kenny served as Vice President and General Manager, U.S. Region, for Becton Dickinson, a medical device company. Prior to 2012, he held executive roles at Danaher Corporation, a science and technology company, and Quest Diagnostics, a medical laboratory company. Mr. Kenny holds a BS degree from Kettering University. - Jack Kenny担任Meridian的首席执行官，于2017年10月9日加入该公司。在加入Meridian之前，Kenny先生曾于2014年10月至2017年5月在西门子梦百合担任北美高级副总裁兼总经理。2012年6月至2014年10月，Kenny先生担任诊断系统公司Becton Dickinson的Vice President兼美国地区总经理。2012年6月之前，Kenny先生在丹纳赫公司和Quest Diagnostics担任执行职务。
- Jack Kenny,has served as a Director of the Company since August 2023. Mr. Kenny is also an independent member of the board of directors for Quantum Si (NASDAQ: QSI), a protein sequencing company, where he has served since May 2023. Mr. Kenny joined Meridian Biosciences ("Meridian"), a life science and diagnostic company, in October 2017, where he served as the Chief Executive Officer and as a member of the board of directors. Mr. Kenny led Meridian's turnaround resulting in the company's sale in January 2023 (to SJL Partners and SD Biosensor). Before his tenure at Meridian, from 2014 to May 2017, Mr. Kenny served as Senior Vice President and General Manager, North America, of Siemens Healthcare, a healthcare company providing healthcare solutions and services. From 2012 to 2014, Mr. Kenny served as Vice President and General Manager, U.S. Region, for Becton Dickinson, a medical device company. Prior to 2012, he held executive roles at Danaher Corporation, a science and technology company, and Quest Diagnostics, a medical laboratory company. Mr. Kenny holds a BS degree from Kettering University.
- Anthony P. Zook
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Felicia Williams
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Stephen M. Kanovsky
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Michael A. Kelly
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- David B. Perez
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Neil Gunn
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Marjorie C. Green
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Anthony P. Zook
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Cynthia J. Dieter
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Warren C. Stone
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Gregory D. Aunan
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Beth Eastland
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Alicia C. Olivo
Alicia C. Olivo于2019年9月加入NeoGenomics，担任公司助理总法律顾问。2022年4月中旬，她开始担任公司临时总法律顾问，一直担任这一职务，直到2022年8月被任命为总法律顾问和公司秘书。Olivo女士拥有超过15年的企业和法律经验。在加入NeoGenomics之前，Olivo女士曾于2017年至2019年在PricewaterhouseCoopers，LLP担任税务业务董事。此前，Olivo女士曾于2008年至2017年在通用电气担任过各种职务，职责不断扩大。Olivo女士拥有佛罗里达大学的学士学位和马凯特大学法学院的京东。
Alicia C. Olivo joined NeoGenomics in September 2019 as the Company's Assistant General Counsel. In mid-April 2022, she began serving as the Company's Interim General Counsel, a role she held until her appointment to General Counsel and Corporate Secretary in August 2022. Ms. Olivo has more than 15 years of corporate and legal experience. Prior to joining NeoGenomics, Ms. Olivo served as a Director in the tax practice at PricewaterhouseCoopers, LLP from 2017 to 2019. Previously, Ms. Olivo held various roles of increasing scope and responsibility at General Electric from 2008 to 2017. Ms. Olivo holds a BS from the University of Florida and a JD from Marquette University School of Law.- Alicia C. Olivo于2019年9月加入NeoGenomics，担任公司助理总法律顾问。2022年4月中旬，她开始担任公司临时总法律顾问，一直担任这一职务，直到2022年8月被任命为总法律顾问和公司秘书。Olivo女士拥有超过15年的企业和法律经验。在加入NeoGenomics之前，Olivo女士曾于2017年至2019年在PricewaterhouseCoopers，LLP担任税务业务董事。此前，Olivo女士曾于2008年至2017年在通用电气担任过各种职务，职责不断扩大。Olivo女士拥有佛罗里达大学的学士学位和马凯特大学法学院的京东。
- Alicia C. Olivo joined NeoGenomics in September 2019 as the Company's Assistant General Counsel. In mid-April 2022, she began serving as the Company's Interim General Counsel, a role she held until her appointment to General Counsel and Corporate Secretary in August 2022. Ms. Olivo has more than 15 years of corporate and legal experience. Prior to joining NeoGenomics, Ms. Olivo served as a Director in the tax practice at PricewaterhouseCoopers, LLP from 2017 to 2019. Previously, Ms. Olivo held various roles of increasing scope and responsibility at General Electric from 2008 to 2017. Ms. Olivo holds a BS from the University of Florida and a JD from Marquette University School of Law.
- Abhishek Jain
Abhishek Jain，此前曾于2022年9月至2025年8月担任CareDx的首席财务官，该公司是一家上市的精准医疗公司，专注于为移植患者和护理人员发现、开发和商业化临床差异化、高价值的医疗保健解决方案。此前曾于2021年8月至2022年5月担任CareDx副总裁、公司控制人，于2022年5月至2022年9月担任CareDx临时首席财务官。在此之前，他曾在为全球制药和诊断实验室提供仪器和服务的安捷伦科技公司担任近20年的财务和会计职务，职责不断增加。最近的一次职务是在2018年5月至2021年8月期间担任WW现场总监。Jain先生是美国科罗拉多州的注册会计师（非在职），也是印度特许会计师协会的特许会计师。
Abhishek Jain,previously served as Chief Financial Officer of CareDx, a publicly traded precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, from September 2022 to August 2025. He previously served as CareDx's Vice President, Corporate Controller from August 2021 to May 2022, and as CareDx's Interim Chief Financial Officer from May 2022 to September 2022. Before that, he served for nearly 20 years in finance and accounting roles of increasing responsibility at Agilent Technologies, Inc., a provider of instruments and services to pharmaceutical and diagnostic laboratories worldwide, and most recently held the position of WW Field Controller from May 2018 to August 2021. Mr. Jain is a Certified Public Accountant (inactive) from the State of Colorado, US and a Chartered Accountant from The Institute of Chartered Accountants of India.- Abhishek Jain，此前曾于2022年9月至2025年8月担任CareDx的首席财务官，该公司是一家上市的精准医疗公司，专注于为移植患者和护理人员发现、开发和商业化临床差异化、高价值的医疗保健解决方案。此前曾于2021年8月至2022年5月担任CareDx副总裁、公司控制人，于2022年5月至2022年9月担任CareDx临时首席财务官。在此之前，他曾在为全球制药和诊断实验室提供仪器和服务的安捷伦科技公司担任近20年的财务和会计职务，职责不断增加。最近的一次职务是在2018年5月至2021年8月期间担任WW现场总监。Jain先生是美国科罗拉多州的注册会计师（非在职），也是印度特许会计师协会的特许会计师。
- Abhishek Jain,previously served as Chief Financial Officer of CareDx, a publicly traded precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, from September 2022 to August 2025. He previously served as CareDx's Vice President, Corporate Controller from August 2021 to May 2022, and as CareDx's Interim Chief Financial Officer from May 2022 to September 2022. Before that, he served for nearly 20 years in finance and accounting roles of increasing responsibility at Agilent Technologies, Inc., a provider of instruments and services to pharmaceutical and diagnostic laboratories worldwide, and most recently held the position of WW Field Controller from May 2018 to August 2021. Mr. Jain is a Certified Public Accountant (inactive) from the State of Colorado, US and a Chartered Accountant from The Institute of Chartered Accountants of India.